Most cancer drugs introduced since 2004 provide low added value compared to previously approved medications, but have much higher prices, according to a French study presented at the congress of the European Society for Medical Oncology [more]
After the European Medicines Agency (EMA) approves a new cancer drug, reimbursement decisions by each country’s health authorities can take up to one year, with wide variations between countries. according to a study just presented [more]
An ESO task force met to discuss the potential for “biosimilar” medical products in oncology, analyzing facts and debunking some myths. Some of the most used biologic drugs in oncology are going off patent in [more]
Dear Alberto, We received the last Cancer World. Congratulations, it’s very nicely formatted, informative, well written and covers topics from a perspective rarely seen in “usual” specialised journals. We were particularly interested by the article [more]
Flexibility and goodwill have allowed patient involvement in the work of Europe’s drug regulators to develop at an impressive pace. But will they be enough to withstand the strains on the relationship exerted by financial [more]
How do you decide which new cancer drugs to approve, when statistical certainty takes too long to wait for and essential evidence on quality of life is hard to measure? The head of the cancer [more]
Little by little, patient advocates are winning their battle to be involved in decisions that affect them. They are now focusing on how to use their new-found voice to deliver real change for the people [more]
When new cancer therapies regularly become available more than half a year earlier in the US than in Europe, or get regulatory approval on one side of the Atlantic but not on the other, patients [more]